Leerink Partners Maintains Outperform on Medline, Raises Price Target to $46
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Michael Cherny maintains Medline (NASDAQ:MDLN) with a Outperform and raises the price target from $43 to $46.
Leerink Partners analyst Michael Cherny maintains Medline (NASDAQ:MDLN) with a Outperform and raises the price target from $43 to $46.